Univeristy of California San Francisco HDF Comprehensive Cancer Center
Welcome,         Profile    Billing    Logout  
 2 Trials 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Shah, Nina
BMTCTN1902, NCT05032820: MM CAR-T to Upgrade Response

Active, not recruiting
2
40
US
Lenalidomide and bb2121, ide-cel, revlimid
Marcelo Pasquini, MD, National Heart, Lung, and Blood Institute (NHLBI), Blood and Marrow Transplant Clinical Trials Network, National Cancer Institute (NCI), National Marrow Donor Program, Celgene a wholly owned subsidiary of BMS
Multiple Myeloma
01/25
04/25
NCT05191472: Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies

Terminated
2
3
US
Pembrolizumab, Keytruda, Lambrolizumab, MK-3475
Alfred Chung, MD, Merck Sharp & Dohme LLC
Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
12/23
12/23
Kilayko, Danielle
No trials found

Download Options